BioAge Labs Net Cash Flow 2024-2025 | BIOA

BioAge Labs net cash flow from 2024 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.

BioAge Labs Net Cash Flow 2024-2025 | BIOA

BioAge Labs net cash flow from 2024 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$229.3B
Amgen (AMGN)$159.6B
Gilead Sciences (GILD)$140.8B
Vertex Pharmaceuticals (VRTX)$118.7B
Bristol Myers Squibb (BMY)$90B
CSL (CSLLY)$82.4B
GSK (GSK)$76.6B
Regeneron Pharmaceuticals (REGN)$60.3B
Alnylam Pharmaceuticals (ALNY)$52.7B
Argenex SE (ARGX)$41.2B
BioNTech SE (BNTX)$25.8B
Royalty Pharma (RPRX)$20.9B
Insmed (INSM)$20.6B
Biogen (BIIB)$19.3B
Illumina (ILMN)$15B
Incyte (INCY)$14.8B
Genmab (GNMSF)$14.7B
Genmab (GMAB)$14B
BioMarin Pharmaceutical (BMRN)$11.1B
QIAGEN (QGEN)$11.1B
Moderna (MRNA)$10.7B
Ascendis Pharma (ASND)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Exelixis (EXEL)$10B
Exact Sciences (EXAS)$9B
Verona Pharma American Depositary Share (VRNA)$9B
Bio-Techne Corp (TECH)$8.6B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$7.7B
Halozyme Therapeutics (HALO)$7.3B